<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25037086</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-9875</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurologic clinics</Title>
          <ISOAbbreviation>Neurol Clin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myotonic dystrophy.</ArticleTitle>
        <Pagination>
          <StartPage>705</StartPage>
          <EndPage>viii</EndPage>
          <MedlinePgn>705-19, viii</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ncl.2014.04.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0733-8619(14)00034-6</ELocationID>
        <Abstract>
          <AbstractText>Myotonic dystrophy (dystrophia myotonica, DM) is one of the most common lethal monogenic disorders in populations of European descent. DM type 1 was first described over a century ago. More recently, a second form of the disease, DM type 2 was recognized, which results from repeat expansion in a different gene. Both disorders have autosomal dominant inheritance and multisystem features, including myotonic myopathy, cataract, and cardiac conduction disease. This article reviews the clinical presentation and pathophysiology of DM and discusses current management and future potential for developing targeted therapies.</AbstractText>
          <CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thornton</LastName>
            <ForeName>Charles A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Center for Neural Development and Disease, Center for RNA Biology, University of Rochester Medical Center, Box 645, 601 Elmwood Avenue, Rochester, NY 14642, USA. Electronic address: charles_thornton@urmc.rochester.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>U54 NS048843</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54NS48843</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>06</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Clin</MedlineTA>
        <NlmUniqueID>8219232</NlmUniqueID>
        <ISSNLinking>0733-8619</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName>
          <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009223" MajorTopicYN="N">Myotonic Dystrophy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Electrophysiology</Keyword>
        <Keyword MajorTopicYN="N">Expanded DNA repeat</Keyword>
        <Keyword MajorTopicYN="N">Myopathy</Keyword>
        <Keyword MajorTopicYN="N">Myotonic dystrophy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25037086</ArticleId>
        <ArticleId IdType="mid">NIHMS589998</ArticleId>
        <ArticleId IdType="pmc">PMC4105852</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ncl.2014.04.011</ArticleId>
        <ArticleId IdType="pii">S0733-8619(14)00034-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Suominen T, Bachinski LL, Auvinen S, et al.  Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet. 2011;19:776–782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137497</ArticleId>
            <ArticleId IdType="pubmed">21364698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norwood FL, Harling C, Chinnery PF, et al.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175–3186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4038491</ArticleId>
            <ArticleId IdType="pubmed">19767415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siciliano G, Manca M, Gennarelli M, et al.  Epidemiology of myotonic dystrophy in Italy: reapprisal after genetic diagnosis. Clin Genet. 2001;59:344–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11359466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magee A, Nevin NC. The epidemiology of myotonic dystrophy in Northern Ireland. Community Genet. 1999;2:179–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14960839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper PS.  Myotonic Dystrophy. W.B. Saunders Company; London: 2001. </Citation>
        </Reference>
        <Reference>
          <Citation>Lotz BP, van der Meyden CH. Myotonic dystrophy. Part I. A genealogical study in the northern Transvaal. S Afr Med J. 1985;67:812–814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3992413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashizawa T, Epstein HF. Ethnic distribution of myotonic dystrophy gene. Lancet. 1991;338:642–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1679186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsiao KM, Chen SS, Li SY, et al.  Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan. Neuroepidemiology. 2003;22:283–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12902623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yotova V, Labuda D, Zietkiewicz E, et al.  Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum Genet. 2005;117:177–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15883838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Udd B, Meola G, Krahe R, et al.  140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord. 2006;16:403–413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16684600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachinski LL, Udd B, Meola G, et al.  Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet. 2003;73:835–848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1180606</ArticleId>
            <ArticleId IdType="pubmed">12970845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brook JD, McCurrach ME, Harley HG, et al.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992;68:799–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1310900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liquori CL, Ricker K, Moseley ML, et al.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864–867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11486088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachinski LL, Czernuszewicz T, Ramagli LS, et al.  Premutation allele pool in myotonic dystrophy type 2. Neurology. 2009;72:490–497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677510</ArticleId>
            <ArticleId IdType="pubmed">19020295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day JW, Ricker K, Jacobsen JF, et al.  Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60:657–664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12601109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redman JB, Fenwick RG, Jr., Fu YH, et al.  Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring. JAMA. 1993;269:1960–1965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8464127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Temmerman N, Sermon K, Seneca S, et al.  Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos. Am J Hum Genet. 2004;75:325–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1216067</ArticleId>
            <ArticleId IdType="pubmed">15185171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashizawa T, Dubel JR, Harati Y. Somatic instability of CTG repeat in myotonic dystrophy. Neurology. 1993;43:2674–2678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8255475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton CA, Johnson K, Moxley RT. Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol. 1994;35:104–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8285579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zatz M, Passos-Bueno MR, Cerqueira A, et al.  Analysis of the CTG repeat in skeletal muscle of young and adult myotonic dystrophy patients: when does the expansion occur? Hum Mol Genet. 1995;4:401–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7795594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamori M, Sobczak K, Puwanant A, et al.  Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol. 2013;74:862–872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4099006</ArticleId>
            <ArticleId IdType="pubmed">23929620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearson CE, Nichol EK, Cleary JD. Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet. 2005;6:729–742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16205713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcelo JM, Mahadevan MS, Tsilfidis C, et al.  Intergenerational stability of the myotonic dystrophy protomutation. Hum Mol Genet. 1993;2:705–709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8353489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsilfidis C, MacKenzie AE, Mettler G, et al.  Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. Nat Genet. 1992;1:192–195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1303233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martorell L, Monckton DG, Sanchez A, et al.  Frequency and stability of the myotonic dystrophy type 1 premutation. Neurology. 2001;56:328–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11171897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashizawa T, Anvret M, Baiget M, et al.  Characteristics of intergenerational contractions of the CTG repeat in myotonic dystrophy. Am J Hum Genet. 1994;54:414–423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1918128</ArticleId>
            <ArticleId IdType="pubmed">8116611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braida C, Stefanatos RK, Adam B, et al.  Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients. Hum Mol Genet. 2010;19:1399–1412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20080938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider C, Ziegler A, Ricker K, et al.  Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. Neurology. 2000;55:383–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10932272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper PS. Congenital myotonic dystrophy in Britain. I. Clinical aspects. Arch Dis Child. 1975;50:505–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1544609</ArticleId>
            <ArticleId IdType="pubmed">1101835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaki M, Boyd PA, Impey L, et al.  Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. Ultrasound Obstet Gynecol. 2007;29:284–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17238150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell C, Levin S, Siu VM, et al.  Congenital myotonic dystrophy: Canadian population-based surveillance study. J Pediatr. 2013;163:120–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23415617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martorell L, Cobo AM, Baiget M, et al.  Prenatal diagnosis in myotonic dystrophy type 1. Thirteen years of experience: implications for reproductive counselling in DM1 families. Prenat Diagn. 2007;27:68–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17154336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ekstrom AB, Hakenas-Plate L, Tulinius M, et al.  Cognition and adaptive skills in myotonic dystrophy type 1: a study of 55 individuals with congenital and childhood forms. Dev Med Child Neurol. 2009;51:982–990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19459914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douniol M, Jacquette A, Cohen D, et al.  Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol. 2012;54:905–911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22861906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeard N, Jacquette A, Gargiulo M, et al.  A new window on neurocognitive dysfunction in the childhood form of myotonic dystrophy type 1 (DM1). Neuromuscul Disord. 2011;21:468–476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21592796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Die-Smulders CE, Howeler CJ, Thijs C, et al.  Age and causes of death in adult-onset myotonic dystrophy. Brain. 1998;121:1557–1563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9712016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groh WJ, Groh MR, Saha C, et al.  Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688–2697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18565861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhakta D, Groh MR, Shen C, et al.  Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. 2010;160:1137–1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21146669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahbi K, Meune C, Becane HM, et al.  Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord. 2009;19:468–472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19481939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoser BG, Ricker K, Schneider-Gold C, et al.  Sudden cardiac death in myotonic dystrophy type 2. Neurology. 2004;63:2402–2404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15623712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bugiardini E, Meola G, on behalf of the DMCNSG  Consensus on cerebral involvement in myotonic dystrophy Workshop report. Neuromuscul Disord. 2014 ePub ahead of print.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24613228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve. 2007;36:294–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17486579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciafaloni E, Mignot E, Sansone V, et al.  The Hypocretin Neurotransmission System in Myotonic Dystrophy Type 1. Neurology. 2007;70:226–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18195268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laberge L, Begin P, Dauvilliers Y, et al.  A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry. 2009;80:642–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19211594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Laberge L, Jaussent I, et al.  Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study. Sleep. 2011;34:165–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3022936</ArticleId>
            <ArticleId IdType="pubmed">21286250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minnerop M, Weber B, Schoene-Bake JC, et al.  The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain. 2011;134:3530–3546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3235566</ArticleId>
            <ArticleId IdType="pubmed">22131273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wozniak JR, Mueller BA, Bell CJ, et al.  Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1. J Neurol. 2013;260:1122–1131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3609908</ArticleId>
            <ArticleId IdType="pubmed">23192171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole C, Bode R, Johnson N, et al.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology. 2012;79:348–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3400095</ArticleId>
            <ArticleId IdType="pubmed">22786587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardani R, Mancinelli E, Saino G, et al.  A putative role of ribonuclear inclusions and MBNL1 in the impairment of gallbladder smooth muscle contractility with cholelithiasis in myotonic dystrophy type 1. Neuromuscul Disord. 2008;18:641–645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18653337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadalla SM, Pfeiffer RM, Kristinsson SY, et al.  Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis. PLoS One. 2013;8:e79851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3827449</ArticleId>
            <ArticleId IdType="pubmed">24236163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadalla SM, Lund M, Pfeiffer RM, et al.  Cancer risk among patients with myotonic muscular dystrophy. JAMA. 2011;306:2480–2486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3286183</ArticleId>
            <ArticleId IdType="pubmed">22166607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Win AK, Perattur PG, Pulido JS, et al.  Increased cancer risks in myotonic dystrophy. Mayo Clin Proc. 2012;87:130–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3498332</ArticleId>
            <ArticleId IdType="pubmed">22237010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peric S, Nisic T, Milicev M, et al.  Hypogonadism and erectile dysfunction in myotonic dystrophy type 1. Acta Myol. 2013;32:106–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3866901</ArticleId>
            <ArticleId IdType="pubmed">24399868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moxley RT, III, Griggs RC, Goldblatt D, et al.  Decreased insulin sensitivity of forearm muscle in myotonic dystrophy. J Clin Invest. 1978;62:857–867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC371838</ArticleId>
            <ArticleId IdType="pubmed">701484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole CR, Miller J, Martens B, et al.  Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol. 2006;63:1149–1153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16908743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Achiron A, Barak Y, Magal N, et al.  Abnormal liver test results in myotonic dystrophy. J Clin Gastroenterol. 1998;26:292–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9649014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sander HW, Tavoulareas GP, Quinto CM, et al.  The exercise test distinguishes proximal myotonic myopathy from myotonic dystrophy. Muscle Nerve. 1997;20:235–237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9040666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fournier E, Viala K, Gervais H, et al.  Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol. 2006;60:356–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16786525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logigian EL, Ciafaloni E, Quinn LC, et al.  Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve. 2007;35:479–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17230537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanisch F, Kronenberger C, Zierz S, et al.  The significance of pathological spontaneous activity in various myopathies. Clin Neurophysiol. 2013 ePub ahead of print.</Citation>
        </Reference>
        <Reference>
          <Citation>Vihola A, Bassez G, Meola G, et al.  Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology. 2003;60:1854–1857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12796551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, Teng-umnuay P, Krym M, et al.  Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol. 2003;54:760–768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14681885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet. 2006;15:R162–R169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16987879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol. 2010;67:291–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2852186</ArticleId>
            <ArticleId IdType="pubmed">20373340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taneja KL, McCurrach M, Schalling M, et al.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995;128:995–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2120416</ArticleId>
            <ArticleId IdType="pubmed">7896884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis BM, McCurrach ME, Taneja KL, et al.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci U S A. 1997;94:7388–7393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC23831</ArticleId>
            <ArticleId IdType="pubmed">9207101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, Lin X, Blaxall BC, et al.  Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res. 2005;97:1152–1155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16254211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Mankodi A, Swanson MS, et al.  Myotonic dystrophy type 1 associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins, and deregulated alternative splicing in neurons. Hum Mol Genet. 2004;13:3079–3088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15496431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, Urbinati CR, Yuan QP, et al.  Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001;10:2165–2170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11590133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JW, Urbinati CR, Teng-umnuay P, et al.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439–4448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC302046</ArticleId>
            <ArticleId IdType="pubmed">10970838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TH, Charlet B, Poulos MG, et al.  Muscleblind proteins regulate alternative splicing. EMBO J. 2004;23:3103–3112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC514918</ArticleId>
            <ArticleId IdType="pubmed">15257297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ET, Cody NA, Jog S, et al.  Transcriptome-wide Regulation of Pre-mRNA Splicing and mRNA Localization by Muscleblind Proteins. Cell. 2012;150:710–724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3428802</ArticleId>
            <ArticleId IdType="pubmed">22901804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Miller JW, Mankodi A, et al.  Failure of MBNL1-dependent postnatal splicing transitions in myotonic dystrophy. Hum Mol Genet. 2006;15:2087–2097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16717059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, Takahashi MP, Jiang H, et al.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell. 2002;10:35–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lueck JD, Mankodi A, Swanson MS, et al.  Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol. 2007;129:79–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2151606</ArticleId>
            <ArticleId IdType="pubmed">17158949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001;29:40–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11528389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fugier C, Klein AF, Hammer C, et al.  Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med. 2011;17:720–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21623381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang ZZ, Yarotskyy V, Wei L, et al.  Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel. Hum Mol Genet. 2011;21:1312–1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3284119</ArticleId>
            <ArticleId IdType="pubmed">22140091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachinski LL, Baggerly KA, Neubauer VL, et al.  Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies. Neuromuscul Disord. 2013 ePub ahead of print.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3943873</ArticleId>
            <ArticleId IdType="pubmed">24332166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007;28:68–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2083558</ArticleId>
            <ArticleId IdType="pubmed">17936705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian B, White RJ, Xia T, et al.  Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA. 2000;6:79–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1369895</ArticleId>
            <ArticleId IdType="pubmed">10668800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998;280:737–741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9563950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zu T, Gibbens B, Doty NS, et al.  Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108:260–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3017129</ArticleId>
            <ArticleId IdType="pubmed">21173221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda M, Taft CS, Bush EW, et al.  Identification, tissue-specific expression, and subcellular localization of the 80- and 71-kDa forms of myotonic dystrophy kinase protein. J Biol Chem. 1995;270:20246–20249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7657592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelletier R, Hamel F, Beaulieu D, et al.  Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol Dis. 2009;36:181–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19632331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raheem O, Olufemi SE, Bachinski LL, et al.  Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2. Am J Pathol. 2010;177:3025–3036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993290</ArticleId>
            <ArticleId IdType="pubmed">20971734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huichalaf C, Schoser B, Schneider-Gold C, et al.  Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci. 2009;29:9042–9049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3610333</ArticleId>
            <ArticleId IdType="pubmed">19605641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margolis JM, Schoser BG, Moseley ML, et al.  DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet. 2006;15:1808–1815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16624843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artero R, Prokop A, Paricio N, et al.  The muscleblind gene participates in the organization of Z-bands and epidermal attachments of Drosophila muscles and is regulated by Dmef2. Dev Biol. 1998;195:131–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9520330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KY, Li M, Manchanda M, et al.  Compound loss of muscleblind-like function in myotonic dystrophy. EMBO molecular medicine. 2013;5:1887–1900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3914532</ArticleId>
            <ArticleId IdType="pubmed">24293317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amack JD, Paguio AP, Mahadevan MS. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet. 1999;8:1975–1984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10484765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poussel M, Kaminsky P, Renaud P, et al.  Supine changes in lung function correlate with chronic respiratory failure in myotonic dystrophy patients. Respir Physiol Neurobiol. 2014;193:43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24440340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNally EM, Sparano D. Mechanisms and management of the heart in myotonic dystrophy. Heart. 2011;97:1094–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4573585</ArticleId>
            <ArticleId IdType="pubmed">21642660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Meche FG, Bogaard JM, van der Sluys JC, et al.  Daytime sleep in myotonic dystrophy is not caused by sleep apnoea. J Neurol Neurosurg Psychiatry. 1994;57:626–628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1072930</ArticleId>
            <ArticleId IdType="pubmed">8201339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology. 2002;59:1876–1880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12499477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlikowski D, Chevret S, Quera-Salva MA, et al.  Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial. Clin Ther. 2009;31:1765–1773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19808135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griggs RC, Pandya S, Florence JM, et al.  Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989;39:219–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2521699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, et al.  Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy--a clinical research center study. J Clin Endocrinol Metab. 1995;80:3715–3723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8530624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole CR, Eichinger KJ, Friedman DI, et al.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol. 2011;68:37–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3374954</ArticleId>
            <ArticleId IdType="pubmed">20837825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trip J, Drost G, van Engelen BG, et al.  Drug treatment for myotonia. Cochrane Database Syst Rev. 2006:CD004762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16437496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logigian EL, Martens WB, Moxley RTt, et al.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010;74:1441–1448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2871004</ArticleId>
            <ArticleId IdType="pubmed">20439846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furling D, Doucet G, Langlois MA, et al.  Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther. 2003;10:795–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12704419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulders SA, van den Broek WJ, Wheeler TM, et al.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009;106:13915–13920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728995</ArticleId>
            <ArticleId IdType="pubmed">19667189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheeler TM, Leger AJ, Pandey SK, et al.  Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature. 2012;488:111–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4221572</ArticleId>
            <ArticleId IdType="pubmed">22859208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coonrod LA, Nakamori M, Wang W, et al.  Reducing levels of toxic RNA with small molecules. ACS Chem Biol. 2013;8:2528–2537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4108295</ArticleId>
            <ArticleId IdType="pubmed">24028068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Childs-Disney JL, Hoskins J, Rzuczek SG, et al.  Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol. 2012;7:856–862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3356481</ArticleId>
            <ArticleId IdType="pubmed">22332923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arambula JF, Ramisetty SR, Baranger AM, et al.  A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci U S A. 2009;106:16068–16073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752522</ArticleId>
            <ArticleId IdType="pubmed">19805260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ofori LO, Hoskins J, Nakamori M, et al.  From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res. 2012;40:6380–6390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401475</ArticleId>
            <ArticleId IdType="pubmed">22492623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang GS, Kuyumcu-Martinez MN, Sarma S, et al.  PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009;119:3797–3806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2786786</ArticleId>
            <ArticleId IdType="pubmed">19907076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanadia RN, Shin J, Yuan Y, et al.  Reversal of RNA mis-splicing and myotonia following muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2006;103:11748–11753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1544241</ArticleId>
            <ArticleId IdType="pubmed">16864772</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
